RBC Bioscience Corporation (TPEX:6848)
Taiwan · Delayed Price · Currency is TWD 16.25
-0.25 (-1.52%)
Feb 11, 2026, 2:07 PM CST
RBC Bioscience Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 19.59 | 21.57 | 6.43 | 3.78 | 28.73 | 141.9 |
Depreciation & Amortization | 16.17 | 17.54 | 18.75 | 19.28 | 19.45 | 13.5 |
Other Amortization | 0.74 | 0.55 | 0.45 | 0.46 | 0.41 | 0.34 |
Loss (Gain) From Sale of Assets | -0 | -0 | 0.02 | -0.01 | 0.54 | -0.09 |
Asset Writedown & Restructuring Costs | - | - | - | - | 0.93 | 9 |
Provision & Write-off of Bad Debts | 0.37 | 0.42 | 0.11 | -0.1 | -0.37 | 0.6 |
Other Operating Activities | 4.55 | 3.43 | -7.15 | 1.3 | -28.74 | 34.4 |
Change in Accounts Receivable | 8.39 | 9.09 | 2.48 | -0.81 | 27.54 | -26.66 |
Change in Inventory | -8.6 | -8.34 | 2.78 | 4 | 9.59 | -35.65 |
Change in Accounts Payable | 0.29 | 8.05 | -6.99 | -13.04 | -65.31 | 73.91 |
Change in Unearned Revenue | -1.25 | 0.79 | 0.06 | -1.11 | 1.06 | -0.89 |
Change in Other Net Operating Assets | -1.8 | 2.83 | -3.73 | -7.14 | -19.11 | -4.67 |
Operating Cash Flow | 38.45 | 55.93 | 13.21 | 6.6 | -25.3 | 205.68 |
Operating Cash Flow Growth | -14.34% | 323.45% | 100.03% | - | - | 412.21% |
Capital Expenditures | -7.65 | -2.13 | -4.99 | -9.96 | -449.72 | -118.41 |
Sale of Property, Plant & Equipment | 0 | 0 | - | 0.01 | 0.01 | 0.2 |
Sale (Purchase) of Intangibles | -8.19 | -8.19 | -1.47 | -0.09 | -0.39 | - |
Other Investing Activities | 0.95 | 0.95 | 7.47 | 22.65 | 24.44 | -1.29 |
Investing Cash Flow | -14.88 | -9.37 | 1 | 12.61 | -425.67 | -119.5 |
Short-Term Debt Issued | - | - | - | - | - | 55 |
Long-Term Debt Issued | - | 35 | 203.46 | - | 404.06 | - |
Total Debt Issued | 35 | 35 | 203.46 | - | 404.06 | 55 |
Short-Term Debt Repaid | - | -10 | -5 | -24.65 | -6.35 | - |
Long-Term Debt Repaid | - | -43.9 | -208.89 | -4.59 | -8.84 | -5.73 |
Total Debt Repaid | -61.34 | -53.9 | -213.89 | -29.24 | -15.19 | -5.73 |
Net Debt Issued (Repaid) | -26.34 | -18.9 | -10.43 | -29.24 | 388.87 | 49.27 |
Issuance of Common Stock | - | - | - | - | 50 | - |
Common Dividends Paid | -12.98 | -12.98 | -14.53 | -11.8 | -14.38 | -54.76 |
Other Financing Activities | - | - | - | 0.29 | - | - |
Financing Cash Flow | -39.31 | -31.88 | -24.96 | -40.75 | 424.49 | -5.49 |
Net Cash Flow | -15.75 | 14.68 | -10.75 | -21.54 | -26.48 | 80.68 |
Free Cash Flow | 30.8 | 53.8 | 8.21 | -3.36 | -475.02 | 87.27 |
Free Cash Flow Growth | -18.85% | 554.94% | - | - | - | 180.87% |
Free Cash Flow Margin | 15.26% | 26.21% | 4.76% | -1.93% | -189.12% | 15.17% |
Free Cash Flow Per Share | 2.14 | 3.75 | 0.57 | -0.23 | -35.11 | 6.60 |
Cash Interest Paid | 10.2 | 10.27 | 10.08 | 7.41 | 5.94 | 1.18 |
Cash Income Tax Paid | 0.74 | 2 | 8.55 | 0 | 36.35 | 3.63 |
Levered Free Cash Flow | 10.07 | 38.36 | 2.95 | 19.92 | -460.85 | 50.35 |
Unlevered Free Cash Flow | 16.43 | 44.81 | 9.2 | 24.66 | -456.89 | 51.09 |
Change in Working Capital | -2.96 | 12.43 | -5.4 | -18.11 | -46.24 | 6.04 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.